Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Metastasis02:30

Metastasis

5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural and functional benchmarking of monolayer- and bioreactor-generated hiPSC-derived cardiomyocytes.

APL bioengineering·2026
Same author

Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.

NPJ breast cancer·2026
Same author

Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.

Advances in therapy·2026
Same author

LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib Resistance.

Molecular & cellular proteomics : MCP·2026
Same author

Targeting FEN1/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer.

Translational oncology·2025
Same author

Metabolic adaptation in epithelial ovarian cancer metastasis.

Biochimica et biophysica acta. Molecular basis of disease·2024

Related Experiment Video

Updated: Jun 14, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K

Leveraging PARP-1/2 to Target Distant Metastasis.

Mallory I Frederick1,2, Djihane Abdesselam1,2, Anna Clouvel2

  • 1Faculty of Medicine, Université de Montréal, Montreal, QC H3C 3T5, Canada.

International Journal of Molecular Sciences
|August 29, 2024
PubMed
Summary

Poly (ADP-Ribose) Polymerase (PARP) inhibitors show promise beyond DNA repair for cancer treatment. These agents can block cancer metastasis through various mechanisms, suggesting broader therapeutic applications.

Keywords:
PARP inhibitorsPARP-1PARP-2cancermetastasistumor microenvironment

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.2K

Related Experiment Videos

Last Updated: Jun 14, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Poly (ADP-Ribose) Polymerase (PARP) inhibitors are established targeted therapies, primarily for BRCA1/2-mutated cancers, by inhibiting DNA repair.
  • PARP-1 and PARP-2 enzymes have roles extending beyond DNA repair, influencing crucial cellular processes.

Purpose of the Study:

  • To review the non-DNA repair functions of PARP-1 and PARP-2.
  • To evaluate the pre-clinical and clinical efficacy of PARP inhibitors in blocking cancer metastasis.
  • To highlight the potential of PARP inhibitors in early cancer settings.

Main Methods:

  • Literature review of pre-clinical studies and clinical advancements.
  • Analysis of PARP inhibitor mechanisms, including DNA repair-dependent and independent pathways.
  • Focus on PARP-1 selective inhibitors and their role in metastasis prevention.

Main Results:

  • PARP-1 influences chemokine signaling, immune modulation, and gene expression related to angiogenesis and epithelial-to-mesenchymal transition (EMT).
  • PARP inhibitors demonstrate efficacy in preclinical models by inhibiting DNA damage, cell migration, invasion, and metastasis formation.
  • Clinical data show PARP inhibitors can prevent and manage distant metastases, with specific efficacy at certain metastatic sites.

Conclusions:

  • PARP inhibitors possess multifaceted roles beyond DNA repair, offering significant potential in combating cancer metastasis.
  • These agents show promise for broader application in early cancer treatment and metastasis prevention.
  • PARP-1 selective inhibitors represent a key area for future therapeutic development in oncology.